Title

Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia
Phase II Efficacy Study of Intramuscular Autologous Bone Marrow Mononuclear Cells Plus Mesenchymal Stem Cell Implantation Versus Autologous Bone Marrow Mononuclear Cells Implantation Only in Patients With Chronic Critical Limb Ischemia
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Status

    Unknown status
  • Study Participants

    50
This is a randomized and single blinded study aimed to compare the efficacy between intramuscular autologous bone marrow mononuclear cells plus mesenchymal stem cell implantation and intramuscular autologous bone marrow mononuclear cells implantation only in patients with chronic critical limb ischemia. Patients will be randomized into two groups of equal number; patients in one group will be implanted with mononuclear cells and mesenchymal stem cells, and the other implanted with mononuclear cells only in the area of affected limb.
When the long blood vessels supplying blood to the arms and legs become blocked (ischemic), patient will experience painful sensations in their calves when they walked which slowly become excruciating painful at rest. When the condition worsens, the patients will not be able to feel any pain from their legs and they will not know if there are any small ulcers or cuts on their legs. As a result, a small ulcer which goes unnoticed becomes bigger and can sometimes become infected. In the worst situations, infection might lead towards gangrene and septicaemia. Severe rest pain and/or ulcerations of ischemic limbs are defined as the state of chronic critical limb ischemia and at this point, amputation of the affected limb is suggested.

Conventional treatments include angioplasty/bypass operation to remove blood vessel blockage to restore blood supply, the use of prescribed medicines to aid in ulcer recovery and clear infection and debridement of damaged/infected tissue. Some procedures have to be performed multiple times. Amputation is inevitable in many cases because some blood capillaries cannot be corrected and restenosis of vessels is very common. Cell therapy with mononuclear cells and mesenchymal stem cells from bone marrow is promising because these stem cells are capable of stimulating and regenerating capillaries and blood vessels.
Study Started
Mar 31
2011
Primary Completion
Dec 31
2015
Anticipated
Study Completion
Feb 29
2016
Anticipated
Last Update
Apr 10
2015
Estimate

Biological Mononuclear and mesenchymal stem cells

Intramuscular administration into the ischemic limb

  • Other names: BM-MNC and BM-MSC

Biological Mononuclear cells

Intramuscular administration into the ischemic limb

  • Other names: BM-MNC

Mononuclear and mesenchymal stem cells Experimental

Autologous bone marrow-derived mononuclear cells and mesenchymal stem cells

Mononuclear cells only Active Comparator

Autologous bone marrow-derived mononuclear cells

Criteria

Inclusion Criteria:

Clinical diagnosis of critical limb ischemia leading to ischemic ulcers in which amputation is indicated
Not suitable for, or remain symptomatic despite angioplasty, bypass operation or collateralization

Exclusion Criteria:

Contraindication to epidural anesthesia and bone marrow aspiration
Contraindication to contrast angiography
Evidence of neoplasia and bone marrow diseases
Any acute or chronic communicable diseases including Hepatitis B, Hepatitis C and HIV
Patients with a limited life expectancy (< 1 year)
Patients with myocardial infarction or stroke within 6 months
Patients with coronary intervention within 6 months
Renal impairment indicated by serum creatinine greater than two times upper limit of the normal range
Liver impairment indicated by serum aspartate transaminase and alanine transaminase greater than two times upper limit of normal
Any other co-morbidity which the physician deems as a contraindication to stem cell transplantation
No Results Posted